- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07937891
The PRECISE-DIET Trial
Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial
People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.
A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.
The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Zandra Overgaard Pedersen, MSc. Health Science
- Telefoonnummer: 24456114
- E-mail: zandra.overgaard.pedersen@regionh.dk
Studie Contact Back-up
- Naam: Bettina Ewers, PhD
- Telefoonnummer: 30912997
- E-mail: bettina.ewers@regionh.dk
Studie Locaties
-
-
-
Herlev, Denemarken, 2730
- Steno Diabetes Center Copenhagen
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- T2D
- Diabetes duration of ≥12 months
- Age ≥18 years
- HbA1c ≥58 mmol/mol
- Attending the SDCC outpatient clinic
- Provided voluntary signed informed consent
Exclusion Criteria:
- Inability to understand the study information
- Medical complications that prevent lowering HbA1c to below 58 mmol/mol
- Use of insulin therapy
- Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
- Systematic use of corticosteroids
- Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
- Circumstances that affect HbA1c (e.g., liver disease and anaemia)
- Known or suspected drug or alcohol abuse
- Pregnancy or breastfeeding or plans of pregnancy within the study period
- Participation in other clinical trials
- Individuals with a BMI of <27 kg/m²
- Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Personalised dietary intervention
CGM-supported personalised carbohydrate recommendations |
Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes. |
|
Actieve vergelijker: Standard dietary counselling
Standard dietary counselling for type 2 diabetes |
Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in HbA1c
Tijdsspanne: Baseline to 6 months
|
Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months |
Baseline to 6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in HbA1c at 12 months
Tijdsspanne: Baseline to 12 weeks and 12 months
|
Between-group difference in HbA1c change (mmol/mol) |
Baseline to 12 weeks and 12 months
|
|
Time in range (TIR)
Tijdsspanne: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose 3.9-10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time above range (TAR)
Tijdsspanne: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose >10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time below range (TBR)
Tijdsspanne: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose <3.9 mmol/L |
Baseline, 6 and 12 months
|
|
Estimated HbA1c
Tijdsspanne: Baseline, 6 and 12 months
|
HbA1c estimated from CGM data (mmol/mol) |
Baseline, 6 and 12 months
|
|
Change in glycaemic variability
Tijdsspanne: Baseline, 6 and 12 months
|
Coefficient of variation (%) derived from CGM |
Baseline, 6 and 12 months
|
|
Body mass index (BMI)
Tijdsspanne: Baseline, 6 and 12 months
|
kg/m² |
Baseline, 6 and 12 months
|
|
Waist and hip circumference
Tijdsspanne: Baseline, 6 and 12 months
|
cm |
Baseline, 6 and 12 months
|
|
Blood pressure
Tijdsspanne: Baseline, 6 and 12 months
|
Systolic and diastolic (mmHg) |
Baseline, 6 and 12 months
|
|
plasma glucose
Tijdsspanne: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Plasma insulin
Tijdsspanne: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
C-peptide
Tijdsspanne: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
Total cholesterol
Tijdsspanne: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
LDL cholesterol
Tijdsspanne: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
HDL cholesterol
Tijdsspanne: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Triglycerides
Tijdsspanne: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Diabetes distress (questionnaire)
Tijdsspanne: Baseline, 6 and 12 months
|
Problem Areas in Diabetes (PAID) score |
Baseline, 6 and 12 months
|
|
Treatment satisfaction (questionnaire)
Tijdsspanne: Baseline, 6 and 12 months
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score |
Baseline, 6 and 12 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in glucose-lowering medication
Tijdsspanne: Baseline, 6 and 12 months
|
Changes in type and dose of glucose-lowering medication |
Baseline, 6 and 12 months
|
|
Personality traits (questionnaire)
Tijdsspanne: Baseline
|
Big Five Inventory (BFI-44) scores |
Baseline
|
|
Dietary intake
Tijdsspanne: Baseline and 6 months
|
Total energy intake and macronutrient composition from a 3-day food record |
Baseline and 6 months
|
|
Physical activity
Tijdsspanne: Baseline and 6 months
|
Physical activity level measured with an AX3 accelerometer worn for 7 days |
Baseline and 6 months
|
|
Carbohydrate estimation ability (questionnaire)
Tijdsspanne: Baseline, 6 and 12 months
|
Accuracy of participants' carbohydrate estimates |
Baseline, 6 and 12 months
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- H-26063596
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .